Metabolic syndrome in prostate cancer: impact on risk and outcomes

被引：13

作者：

Karzai, Fatima H. ^{[1
]}

Madan, Ravi A. ^{[1
]}

Dahut, William L. ^{[1
]}

机构：

[1] NCI, Genitourinary Malignancies Branch, NIH, Bethesda, MD 20892 USA

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 16期

关键词：

androgen-deprivation therapy; androgen receptor; cardiovascular risk; diabetes; gonadotropin-releasing hormone agonist/antagonist; hypertriglyceridemia; insulin resistance; metabolic syndrome; prostate cancer; ANDROGEN-DEPRIVATION THERAPY; INSULIN-RESISTANCE; CARDIOVASCULAR MORTALITY; RADICAL PROSTATECTOMY; ASSOCIATION; MEN; ENZALUTAMIDE; BLOCKADE; ESTROGEN; OBESITY;

D O I：

10.2217/fon-2016-0061

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Androgen-deprivation therapy (ADT) is a fundamental element of treatment for nonlocalized prostate cancer and for patients with high-risk disease who are not candidates for radical treatment. ADT has been linked to metabolic syndrome, which involves changes in metabolic factors. While distinct from classic metabolic syndrome, this type does include changes in body composition, lipid profiles and insulin resistance. The constellation of risk factors may be associated with cardiovascular morbidity and the onset of diabetes mellitus. Physicians should discuss in detail the risk and benefits of ADT, as well as any needed lifestyle modifications with patients before beginning therapy.

引用

页码：1947 / 1955

页数：9

共 54 条

[1]

[Anonymous], 2011, NEW ENGL J MED

[2] Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer [J].

Attard, G ;

Belldegrun, AS ;

de Bono, JS .

BJU INTERNATIONAL, 2005, 96 (09) :1241-1246

[3] Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy [J].

Basaria, S ;

Muller, DC ;

Carducci, MA ;

Egan, J ;

Dobs, AS .

CANCER, 2006, 106 (03) :581-588

[4] High-Risk Prostate Cancer: From Definition to Contemporary Management [J].

Bastian, Patrick J. ;

Boorjian, Stephen A. ;

Bossi, Alberto ;

Briganti, Alberto ;

Heidenreich, Axel ;

Freedland, Stephen J. ;

Montorsi, Francesco ;

Roach, Mack, III ;

Schroder, Fritz ;

van Poppel, Hein ;

Stief, Christian G. ;

Stephenson, Andrew J. ;

Zelefsky, Michael J. .

EUROPEAN UROLOGY, 2012, 61 (06) :1096-1106

[5]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[6] Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort [J].

Bhindi, Bimal ;

Locke, Jennifer ;

Alibhai, Shabbir M. H. ;

Kulkarni, Girish S. ;

Margel, David S. ;

Hamilton, Robert J. ;

Finelli, Antonio ;

Trachtenberg, John ;

Zlotta, Alexandre R. ;

Toi, Ants ;

Hersey, Karen M. ;

Evans, Andrew ;

van der Kwast, Theodorus H. ;

Fleshner, Neil E. .

EUROPEAN UROLOGY, 2015, 67 (01) :64-70

[7] External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study [J].

Bolla, Michel ;

Van Tienhoven, Geertjan ;

Warde, Padraig ;

Dubois, Jean Bernard ;

Mirimanoff, Rene-Olivier ;

Storme, Guy ;

Bernier, Jacques ;

Kuten, Abraham ;

Sternberg, Cora ;

Billiet, Ignace ;

Lopez Torecilla, Jose ;

Pfeffer, Raphael ;

Cutajar, Carmel Lino ;

Van der Kwast, Theodore ;

Collette, Laurence .

LANCET ONCOLOGY, 2010, 11 (11) :1066-1073

[8] Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy [J].

Braga-Basaria, Milena ;

Dobs, Adrian S. ;

Muller, Denis C. ;

Carducci, Michael A. ;

John, Majnu ;

Egan, Josephine ;

Basaria, Shehzad .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3979-3983

[9] Molecular determinants of resistance to antiandrogen therapy [J].

Chen, CD ;

Welsbie, DS ;

Tran, C ;

Baek, SH ;

Chen, R ;

Vessella, R ;

Rosenfeld, MG ;

Sawyers, CL .

NATURE MEDICINE, 2004, 10 (01) :33-39

[10] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

← 1 2 3 4 5 6 →